IPR and technological issues regarding a biopharmaceutical formulation hemoglobin.
Recent Pat Biotechnol
; 2(1): 60-7, 2008.
Article
in En
| MEDLINE
| ID: mdl-19075854
ABSTRACT
Hemoglobin, the protein responsible for the red color of blood plays a very important part in 'life'- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this 'life-saving' protein. There are more than 250 patents worldwide related to hemoglobin formulation, cross-linking and determination.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Patents as Topic
/
Biopharmaceutics
/
Blood Substitutes
/
Biotechnology
/
Hemoglobins
/
Drug Design
/
Technology, Pharmaceutical
Language:
En
Journal:
Recent Pat Biotechnol
Journal subject:
BIOTECNOLOGIA
Year:
2008
Document type:
Article
Affiliation country: